Skip to main content
Premium Trial:

Request an Annual Quote

Prodesse Flu Assay Gets Additional FDA Claims

NEW YORK (GenomeWeb News) – Molecular diagnostics company Prodesse said today that the US Food and Drug Administration has authorized two changes to the packaging on the company’s influenza assay.
 
The FDA, which cleared the company’s ProFlu+ at the beginning of 2008, has accepted using the bioMérieux NucliSENS easyMAG automated nucleic acid extraction system with the ProFlu+ test, the company said.
 
The FDA also has removed a recommendation that negative results for influenza A and influenza B should be confirmed by culture. That makes this test the first molecular test for respiratory viruses that the FDA has decided does not require a backup, the Milwaukee, Wis.-based company said.
 
Prodesse CEO Tom Shannon said that “only a test that shows exceptional performance compared to culture can have this recommendation removed.”
 
The ProFlu Assay is designed to simultaneously detect and differentiate influenza A and B viruses and respiratory syncytial virus, and provides results in around three hours.
The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.